Tamoxifen and Cisplatin for Melanoma Treatment
Author Information
Author(s): McClay E F, McClay M E T, Monroe L, Baron P L, Cole D J, O'Brien P H, Metcalf J S, Maize J C
Primary Institution: University of California, San Diego
Hypothesis
Does the combination of tamoxifen and cisplatin improve disease-free and overall survival in high-risk malignant melanoma patients?
Conclusion
Tamoxifen and cisplatin positively impact disease-free and overall survival in high-risk malignant melanoma patients.
Supporting Evidence
- The disease-free survival (DFS) is 68.4% and overall survival (OS) is 84.5% after 36 months.
- Kaplan–Meier analysis predicts a 5-year DFS of 62% and OS of 79%.
- Relapses after 20 months have been rare.
- The major toxicity was gastrointestinal, with nausea being the most prevalent symptom.
Takeaway
This study tested a combination of two drugs, tamoxifen and cisplatin, to help people with a serious skin cancer called melanoma live longer and stay healthier after treatment.
Methodology
Phase II trial with 153 patients receiving 4 cycles of tamoxifen and cisplatin, followed by regular evaluations.
Limitations
The study's results are preliminary and need confirmation in a larger randomized trial.
Participant Demographics
Patients with high-risk malignant melanoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website